Medical Condition News

RSS

Plymouth scientists receive MRC grant to lead new and effective therapies for Parkinson's disease

A team of scientists led by researchers at Plymouth University Peninsula Schools of Medicine and Dentistry, has received a grant from the Medical Research Council (MRC) for work which could lead to new and effective therapies for those with Parkinson's Disease.

23 Apr 2014

VHVI implants miniaturized HeartWare HVAD Pump through minimally invasive approach

Sometimes smaller is better. This is especially true of left ventricular assist devices, the mechanically operated heart pumps that are implanted in heart failure patients to bridge them to transplantation.

23 Apr 2014

Avedro receives Canadian approval for KXL II System

Avedro Inc., a Boston-based ophthalmic medical device and pharmaceutical company announces today the Canadian approval for the company's KXL II System. The KXL II System performs a procedure called PiXL (Photorefractive Intrastromal Cross-Linking) which has the potential to deliver non-surgical correction of myopia, and improve cataract surgery outcomes.

23 Apr 2014

Study: Excessive fetal growth increases risk of stillbirth

Researchers from the University of Texas Medical Branch and the Stillbirth Collaborative Research Network have identified a link between stillbirth and either restricted or excessive fetal growth. Findings from the study are online in the April 22 issue of PLOS Medicine.

23 Apr 2014

Drug used to treat hypertension prevents post-traumatic epilepsy in rodent model

Between 10 and 20 percent of all cases of epilepsy result from severe head injury, but a new drug promises to prevent post-traumatic seizures and may forestall further brain damage caused by seizures in those who already have epilepsy.

23 Apr 2014

New studies may offer hope for people with migraine

Two new studies may offer hope for people with migraine. The two studies released today will be presented at the American Academy of Neurology's 66th Annual Meeting in Philadelphia, April 26 to May 3, 2014.

23 Apr 2014

NeuroPhage engineers series of molecules with potential to treat most neurodegenerative diseases

Researchers from NeuroPhage Pharmaceuticals, Inc. have engineered a series of molecules with the potential to treat most neurodegenerative diseases that are characterized by misfolded proteins, such as Alzheimer's, Parkinson's and Huntington's diseases.

23 Apr 2014

New FDA-approved device reduces seizures in patients with medication-resistant epilepsy

A recently FDA-approved device has been shown to reduce seizures in patients with medication-resistant epilepsy by as much as 50 percent. When coupled with an innovative electrode placement planning system developed by physicians at Rush, the device facilitated the complete elimination of seizures in nearly half of the implanted Rush patients enrolled in the decade-long clinical trials.

23 Apr 2014

New computational tool identifies undiagnosed illnesses and unknown gene mutations

A computational tool developed at the University of Utah (U of U) has successfully identified diseases with unknown gene mutations in three separate cases, U of U researchers and their colleagues report in a new study in The American Journal of Human Genetics.

23 Apr 2014

New painkiller, with fewer side-effects, up for FDA approval

The drug, Moxduo, allows patients to take lower doses of other painkillers. Elsewhere, a Food and Drug Administration official talks about another painkiller, Zohydro.

23 Apr 2014

Bayer's Ciprofloxacin DPI receives FDA orphan drug designation for NCFB treatment

Bayer HealthCare today announced that the U.S. Food and Drug Administration's Office of Orphan Products Development has granted orphan drug designation for its investigational Ciprofloxacin Dry Powder for Inhalation (Ciprofloxacin DPI) for the treatment of non-cystic fibrosis bronchiectasis (NCFB).

23 Apr 2014

Pfizer reports positive results from two tofacitinib Phase 3 trials for moderate-to-severe plaque psoriasis

Pfizer Inc. announced today top-line results from two pivotal Phase 3 trials from the Oral treatment Psoriasis Trials (OPT) Program, OPT Pivotal #1 (A3921078) and OPT Pivotal #2 (A3921079), evaluating the efficacy and safety of tofacitinib, an oral Janus kinase (JAK) inhibitor, the first in a new class of medicines being investigated for the treatment of moderate-to-severe plaque psoriasis.

23 Apr 2014

FDA approves Cyramza to treat patients with advanced stomach cancer

Based on results of a clinical trial led by Dana-Farber Cancer Institute scientists, the U.S. Food and Drug Administration (FDA) approved a molecularly targeted drug as second-line treatment in advanced stomach cancer that has progressed after standard chemotherapy has failed.

22 Apr 2014

Older parents are more likely to have child with autism spectrum disorder, says study

Older parents are more likely to have a child who develops an autism spectrum disorder (ASD) than are younger parents. A recent study from researchers from the Drexel University School of Public Health in Philadelphia and Karolinska Institute in Sweden provides more insight into how the risk associated with parental age varies between mothers' and fathers' ages, and found that the risk of having a child with both ASD and intellectual disability is larger for older parents.

22 Apr 2014

Cedars-Sinai researchers to receive $8M grant to fund Phase II clinical trial of experimental drug for stroke

Cedars-Sinai stroke intervention researchers have been informed that the National Institute of Neurological Disorders and Stroke, part of the National Institutes of Health, will award an $8 million grant to fund a multicenter Phase II clinical trial of an experimental drug for stroke.

22 Apr 2014

OncoSec to present update of data from Phase 2 melanoma study at ASCO Annual Meeting

OncoSec Medical Inc., a company developing its ImmunoPulse DNA-based immunotherapy to treat solid tumors, will present an update of data from their Phase 2 melanoma study at the American Society of Clinical Oncology's 50th Annual Meeting, taking place May 30-June 3, 2014, at McCormick Place in Chicago, Illinois.

22 Apr 2014

FDA announces expanded approval of Arzerra in combination with chlorambucil for CLL treatment

The US Food and Drug Administration has announced the expanded approval of Arzerra (ofatumumab) in combination with chlorambucil for the first-line treatment of chronic lymphocytic leukemia (CLL). Arzerra was previously approved by the FDA in October 2009 for the treatment of CLL resistant to other forms of chemotherapy. Diplomat has access to dispense Arzerra.

22 Apr 2014

Sleep disorder is the best current predictor of brain diseases, say U of T researchers

Researchers at the University of Toronto say a sleep disorder that causes people to act out their dreams is the best current predictor of brain diseases like Parkinson's and Alzheimer's.

22 Apr 2014

Researchers aim at developing mobile phone app that can diagnose cancer

Plans to design a smart phone app that can detect leukaemia will be among the innovations presented by Northumbria University researchers at the Centre for Life this weekend.

22 Apr 2014

Ockham to partner with Leukemia and Lymphoma Society to increase commitment to cancer philanthropy

Ockham Development will partner with the Leukemia and Lymphoma Society of North Carolina chapter during 2014 to increase its commitment to cancer-directed philanthropy and collaborate with the Society to support the company's personal health and fitness goals.

22 Apr 2014

Medical Condition News

Plymouth scientists receive MRC grant to lead new and effective therapies for Parkinson's disease

VHVI implants miniaturized HeartWare HVAD Pump through minimally invasive approach

Avedro receives Canadian approval for KXL II System

Study: Excessive fetal growth increases risk of stillbirth

Drug used to treat hypertension prevents post-traumatic epilepsy in rodent model

New studies may offer hope for people with migraine

NeuroPhage engineers series of molecules with potential to treat most neurodegenerative diseases

New FDA-approved device reduces seizures in patients with medication-resistant epilepsy

New computational tool identifies undiagnosed illnesses and unknown gene mutations

New painkiller, with fewer side-effects, up for FDA approval

Bayer's Ciprofloxacin DPI receives FDA orphan drug designation for NCFB treatment

Pfizer reports positive results from two tofacitinib Phase 3 trials for moderate-to-severe plaque psoriasis

FDA approves Cyramza to treat patients with advanced stomach cancer

Older parents are more likely to have child with autism spectrum disorder, says study

Cedars-Sinai researchers to receive $8M grant to fund Phase II clinical trial of experimental drug for stroke

OncoSec to present update of data from Phase 2 melanoma study at ASCO Annual Meeting

FDA announces expanded approval of Arzerra in combination with chlorambucil for CLL treatment

Sleep disorder is the best current predictor of brain diseases, say U of T researchers

Researchers aim at developing mobile phone app that can diagnose cancer

Ockham to partner with Leukemia and Lymphoma Society to increase commitment to cancer philanthropy

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Latest News